ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research

Zacks Research upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY) from a strong sell rating to a hold rating in a report published on Wednesday morning,Zacks.com reports.

Several other research analysts have also issued reports on the company. Roth Mkm assumed coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.67.

ARS Pharmaceuticals Trading Down 0.6%

SPRY stock opened at $9.28 on Wednesday. ARS Pharmaceuticals has a 1-year low of $6.66 and a 1-year high of $18.90. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. The business’s 50 day moving average is $10.42 and its 200-day moving average is $10.37. The firm has a market cap of $917.33 million, a P/E ratio of -11.46 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American Assets Inc. acquired a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at $553,000. Geode Capital Management LLC grew its stake in shares of ARS Pharmaceuticals by 6.5% during the second quarter. Geode Capital Management LLC now owns 1,342,387 shares of the company’s stock worth $23,427,000 after purchasing an additional 81,910 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in ARS Pharmaceuticals in the second quarter valued at about $1,832,000. Ardsley Advisory Partners LP lifted its stake in ARS Pharmaceuticals by 46.2% in the second quarter. Ardsley Advisory Partners LP now owns 475,000 shares of the company’s stock valued at $8,289,000 after buying an additional 150,000 shares during the period. Finally, Levin Capital Strategies L.P. lifted its stake in ARS Pharmaceuticals by 157.6% in the third quarter. Levin Capital Strategies L.P. now owns 764,294 shares of the company’s stock valued at $7,681,000 after buying an additional 467,647 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.